It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Obesity is strongly correlated with lipotoxic cardiomyopathy, heart failure and thus mortality. The incidence of obesity has reached alarming proportions worldwide, and increasing evidence suggests that the parents’ nutritional status may predispose their offspring to lipotoxic cardiomyopathy. However, to date, mechanisms underlying intergenerational heart disease risks have yet to be elucidated. Here we report that cardiac dysfunction induced by high-fat-diet (HFD) persists for two subsequent generations in Drosophila and is associated with reduced expression of two key metabolic regulators, adipose triglyceride lipase (ATGL/bmm) and transcriptional cofactor PGC-1. We provide evidence that targeted expression of ATGL/bmm in the offspring of HFD-fed parents protects them, and the subsequent generation, from cardio-lipotoxicity. Furthermore, we find that intergenerational inheritance of lipotoxic cardiomyopathy correlates with elevated systemic H3K27 trimethylation. Lowering H3K27 trimethylation genetically or pharmacologically in the offspring of HFD-fed parents prevents cardiac pathology. This suggests that metabolic homeostasis is epigenetically regulated across generations.
Animal studies have shown that the nutritional status of parents can predispose the offspring to obesity and obesity-related diseases. Here the authors show that cardiac dysfunction induced by a high-fat diet persists for two generations in Drosophila, and that targeted expression of ATGL/bmm in the offspring, as well as inhibition of H3K27 trimethylation, is cardioprotective.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Sanford-Burnham-Prebys Medical Discovery Institute, Development, Aging and Regeneration Program, La Jolla, USA (GRID:grid.479509.6) (ISNI:0000 0001 0163 8573)
2 Sanford-Burnham-Prebys Medical Discovery Institute, Development, Aging and Regeneration Program, La Jolla, USA (GRID:grid.479509.6) (ISNI:0000 0001 0163 8573) ; Biocompatibles Inc., West Conshohocken, USA (GRID:grid.479509.6)
3 Sanford-Burnham-Prebys Medical Discovery Institute, Development, Aging and Regeneration Program, La Jolla, USA (GRID:grid.479509.6) (ISNI:0000 0001 0163 8573) ; Whitehead Institute for Biomedical Research, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786)
4 Sapienza Università di Roma, Rome, Italy (GRID:grid.7841.a)
5 Sanford-Burnham-Prebys Medical Discovery Institute, Development, Aging and Regeneration Program, La Jolla, USA (GRID:grid.479509.6) (ISNI:0000 0001 0163 8573) ; IRCCS Fondazione Santa Lucia, Rome, Italy (GRID:grid.417778.a) (ISNI:0000 0001 0692 3437)